I've checked again and there is still zero prospective studies on cyamemazine, the most commonly prescriped neuroleptic here, allowed in liquid form at age 3.
Hello, thank you for this article that highlights the deterioration of health and mentality in France. I am a psychiatrist, 56 years old, and I practiced in Paris and the surrounding region, first in a university hospital and then in private practice until 2019. Throughout my career, I have always prescribed LT3, which has been referred to for many years as an adjunct treatment for antidepressants in resistant depression (though without scientifically proven effectiveness, nor personal observation). I have also prescribed pramipexole (unfortunately not very effective and generating quite a few side effects when the dose is increased), lamotrigine - one of the best-tolerated and very effective mood stabilizers, whether used alone or in combination with lithium to enhance antidepressant effects, and oxcarbazepine (as a mood stabilizer), among others. Currently, I prescribe SEMAGLUTIDE to my patients with severe obesity without diabetes, with reimbursement, and monitoring of liver elastography shows improvement after one year of treatment. Therefore, the fact that this colleague has faced so many problems shocks me and indicates a regression in the mentality of healthcare professionals and the health insurance system.
This is absolutely bizarre to me, pramipexole is regularly used by psychiatrists in the UK for bipolar depression. I use levothyroxine augmentation myself and I'm not even a consultant yet. And the discrimination on top! Sending all my support to Dr Sikorav having to work in this kind of system.
My experience of GMC prolonged investigation after helping a patient during the pandemic made me very aware of the rigid rules based approach these regulators have, I was really surprised to find that absence of harm, clinical need and even GMC own pandemic guidelines were seen as completely irrelevant to forcing me to go through a 2 year process whose point I realised afterwards was forcing me to perform submission dressed up as giving me a legal defence. At least I was able to share my learning from the process https://medium.com/@doctor_27995/surviving-the-storm-reflections-on-gmc-investigation-for-neurodivergent-and-female-doctors-802866126944
Thank you for sharing my story Awais !
I've checked again and there is still zero prospective studies on cyamemazine, the most commonly prescriped neuroleptic here, allowed in liquid form at age 3.
What a mess
Hello, thank you for this article that highlights the deterioration of health and mentality in France. I am a psychiatrist, 56 years old, and I practiced in Paris and the surrounding region, first in a university hospital and then in private practice until 2019. Throughout my career, I have always prescribed LT3, which has been referred to for many years as an adjunct treatment for antidepressants in resistant depression (though without scientifically proven effectiveness, nor personal observation). I have also prescribed pramipexole (unfortunately not very effective and generating quite a few side effects when the dose is increased), lamotrigine - one of the best-tolerated and very effective mood stabilizers, whether used alone or in combination with lithium to enhance antidepressant effects, and oxcarbazepine (as a mood stabilizer), among others. Currently, I prescribe SEMAGLUTIDE to my patients with severe obesity without diabetes, with reimbursement, and monitoring of liver elastography shows improvement after one year of treatment. Therefore, the fact that this colleague has faced so many problems shocks me and indicates a regression in the mentality of healthcare professionals and the health insurance system.
thank you for this, our field is a wreck on the very best day, a noble well intentioned wreck, but a wreck nonetheless
This is absolutely bizarre to me, pramipexole is regularly used by psychiatrists in the UK for bipolar depression. I use levothyroxine augmentation myself and I'm not even a consultant yet. And the discrimination on top! Sending all my support to Dr Sikorav having to work in this kind of system.
My experience of GMC prolonged investigation after helping a patient during the pandemic made me very aware of the rigid rules based approach these regulators have, I was really surprised to find that absence of harm, clinical need and even GMC own pandemic guidelines were seen as completely irrelevant to forcing me to go through a 2 year process whose point I realised afterwards was forcing me to perform submission dressed up as giving me a legal defence. At least I was able to share my learning from the process https://medium.com/@doctor_27995/surviving-the-storm-reflections-on-gmc-investigation-for-neurodivergent-and-female-doctors-802866126944